The Dangers of Using Cq to Quantify Nucleic Acid in Biological Samples : A Lesson From COVID-19
© American Association for Clinical Chemistry 2021..
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA quantities, measured by reverse transcription quantitative PCR (RT-qPCR), have been proposed to stratify clinical risk or determine analytical performance targets. We investigated reproducibility and how setting diagnostic cutoffs altered the clinical sensitivity of coronavirus disease 2019 (COVID-19) testing.
METHODS: Quantitative SARS-CoV-2 RNA distributions [quantification cycle (Cq) and copies/mL] from more than 6000 patients from 3 clinical laboratories in United Kingdom, Belgium, and the Republic of Korea were analyzed. Impact of Cq cutoffs on clinical sensitivity was assessed. The June/July 2020 INSTAND external quality assessment scheme SARS-CoV-2 materials were used to estimate laboratory reported copies/mL and to estimate the variation in copies/mL for a given Cq.
RESULTS: When the WHO-suggested Cq cutoff of 25 was applied, the clinical sensitivity dropped to about 16%. Clinical sensitivity also dropped to about 27% when a simulated limit of detection of 106 copies/mL was applied. The interlaboratory variation for a given Cq value was >1000 fold in copies/mL (99% CI).
CONCLUSION: While RT-qPCR has been instrumental in the response to COVID-19, we recommend Cq (cycle threshold or crossing point) values not be used to set clinical cutoffs or diagnostic performance targets due to poor interlaboratory reproducibility; calibrated copy-based units (used elsewhere in virology) offer more reproducible alternatives. We also report a phenomenon where diagnostic performance may change relative to the effective reproduction number. Our findings indicate that the disparities between patient populations across time are an important consideration when evaluating or deploying diagnostic tests. This is especially relevant to the emergency situation of an evolving pandemic.
| Errataetall: |
CommentIn: Clin Chem. 2021 Dec 30;68(1):7-9. - PMID 34677605 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Clinical chemistry - 68(2021), 1 vom: 30. Dez., Seite 153-162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Evans, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cycle threshold |
|---|
| Anmerkungen: |
Date Completed 02.02.2022 Date Revised 24.04.2022 published: Print CommentIn: Clin Chem. 2021 Dec 30;68(1):7-9. - PMID 34677605 Citation Status MEDLINE |
|---|
| doi: |
10.1093/clinchem/hvab219 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331739402 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331739402 | ||
| 003 | DE-627 | ||
| 005 | 20231225214126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/clinchem/hvab219 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331739402 | ||
| 035 | |a (NLM)34633030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Evans, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Dangers of Using Cq to Quantify Nucleic Acid in Biological Samples |b A Lesson From COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2022 | ||
| 500 | |a Date Revised 24.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Chem. 2021 Dec 30;68(1):7-9. - PMID 34677605 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © American Association for Clinical Chemistry 2021. | ||
| 520 | |a BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA quantities, measured by reverse transcription quantitative PCR (RT-qPCR), have been proposed to stratify clinical risk or determine analytical performance targets. We investigated reproducibility and how setting diagnostic cutoffs altered the clinical sensitivity of coronavirus disease 2019 (COVID-19) testing | ||
| 520 | |a METHODS: Quantitative SARS-CoV-2 RNA distributions [quantification cycle (Cq) and copies/mL] from more than 6000 patients from 3 clinical laboratories in United Kingdom, Belgium, and the Republic of Korea were analyzed. Impact of Cq cutoffs on clinical sensitivity was assessed. The June/July 2020 INSTAND external quality assessment scheme SARS-CoV-2 materials were used to estimate laboratory reported copies/mL and to estimate the variation in copies/mL for a given Cq | ||
| 520 | |a RESULTS: When the WHO-suggested Cq cutoff of 25 was applied, the clinical sensitivity dropped to about 16%. Clinical sensitivity also dropped to about 27% when a simulated limit of detection of 106 copies/mL was applied. The interlaboratory variation for a given Cq value was >1000 fold in copies/mL (99% CI) | ||
| 520 | |a CONCLUSION: While RT-qPCR has been instrumental in the response to COVID-19, we recommend Cq (cycle threshold or crossing point) values not be used to set clinical cutoffs or diagnostic performance targets due to poor interlaboratory reproducibility; calibrated copy-based units (used elsewhere in virology) offer more reproducible alternatives. We also report a phenomenon where diagnostic performance may change relative to the effective reproduction number. Our findings indicate that the disparities between patient populations across time are an important consideration when evaluating or deploying diagnostic tests. This is especially relevant to the emergency situation of an evolving pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a RT-qPCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cycle threshold | |
| 650 | 4 | |a quantification cycle | |
| 650 | 7 | |a Nucleic Acids |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Cowen, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Kammel, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a O'Sullivan, Denise M |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Grunert, Hans-Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Moran-Gilad, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Verwilt, Jasper |e verfasserin |4 aut | |
| 700 | 1 | |a In, Jiwon |e verfasserin |4 aut | |
| 700 | 1 | |a Vandesompele, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Ki Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Storey, Nathaniel |e verfasserin |4 aut | |
| 700 | 1 | |a Hingley-Wilson, Suzie |e verfasserin |4 aut | |
| 700 | 1 | |a Dühring, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Young-Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Foy, Carole A |e verfasserin |4 aut | |
| 700 | 1 | |a Braybrook, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Zeichhardt, Heinz |e verfasserin |4 aut | |
| 700 | 1 | |a Huggett, Jim F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry |d 1955 |g 68(2021), 1 vom: 30. Dez., Seite 153-162 |w (DE-627)NLM000002003 |x 1530-8561 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2021 |g number:1 |g day:30 |g month:12 |g pages:153-162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/clinchem/hvab219 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2021 |e 1 |b 30 |c 12 |h 153-162 | ||